Adjuvant Global Health Technology Fund, L.P.'s Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Jan 18, 2024
- Accession no.
- 0000950170-24-005513
- Filed
- Jan 18, 2024, 6:18 PM ET
- Trade date
- Jan 16, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.97M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Adjuvant Global Health Technology Fund, L.P.CIK 0001783165 | 10% Owner |
| Adjuvant Global Health Technology Fund DE, L.P.CIK 0001799812 | 10% Owner |
| Adjuvant Capital Management, LLCCIK 0001935084 | 10% Owner |
| Adjuvant Capital GP, L.P.CIK 0001935100 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Common Stock | SSaleDisposed | −84,093 | $19.65 | −$1,652,427.45 | 1,995,958 | Direct | |
| Jan 16, 2024 | Common Stock | SSaleDisposed | −15,907 | $19.65 | −$312,572.55 | 377,542 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.